formula

Reckitt Benckiser ‘may shelve plan to sell infant-nutrition unit’

UK consumer goods major Reckitt Benckiser is reportedly considering postponing plans to sell its infant-formula unit.

News agency Bloomberg, quoting unnamed sources familiar with the situation, said the sale, reputedly worth US$7bn, has fallen victim to “chaos in the industry and worsening financing markets”.

The company reportedly kicked off plans to sell its remaining businesses in infant formula in April and was said to be working with advisers on moves to sell the assets, which include the Enfamil brand. A

Read the rest

EXPLAINER: What we know about shuttered baby formula plant

WASHINGTON (AP) — At the center of the nationwide baby formula shortage is a single factory: Abbott Nutrition’s plant that has been closed for more than three months because of contamination problems.

On Monday, U.S. officials announced a deal with Abbott that paves the way to restart production at the Sturgis, Michigan, facility, the largest in the U.S. and source of leading brands like Similac.

But it’s not yet clear how soon the site will be up and running. And even bigger questions remain unanswered, including what caused the contamination and whether U.S. regulators could have alleviated the current formula shortage by stepping in sooner. The plant shutdown exacerbated ongoing supply chain problems among U.S. formula makers.

WHAT CAUSED THE SHUTDOWN?

In mid-February, Abbott announced it was recalling various lots of three powdered infant formulas from the plant, after federal officials began investigating rare bacterial infections in four babies who

Read the rest

Abbott Nutrition restarts baby formula production in reopened Michigan plant

Shelves normally meant for baby formula sit nearly empty at a store in downtown Washington, DC, on May 22, 2022.

Samuel Corum | AFP | Getty Images

Abbott Nutrition on Saturday resumed baby formula production at its Sturgis, Michigan, plant, a move toward addressing a nationwide shortage.

The company has been given the green light from the U.S. Food and Drug Administration after meeting “initial requirements” as part of a May 16 consent decree.

The company said it will restart the production of EleCare, a formula for children who struggle to digest other products, along with other specialty and metabolic formulas.

Abbott aims for an initial EleCare product release around June 20 and is working to meet guidelines to resume production of Similac and other formulas.

“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” a

Read the rest